Ortho Regenerative Technologies Inc. (CSE: ORTH.CN) an emerging Orthopaedic and Sports Medicine Technology company, today announced it has received a Notice of Allowance from the European Patent Office for European Patent Application Number 10831011.1 entitled, “Soluble Physiological Chitosan Formulations Combined with Platelet-Rich Plasma for Tissue Repair.” 

Once the administrative process is complete, the European Patent that issues from this application will provide intellectual property protection for the formulation of Ortho RTi’s ‘Ortho-R’ for the biologic repair of tissue.   

“This allowance adds to the formidable intellectual property estate that we are building to cover our game-changing propriety biopolymer platform around the globe,” said Ortho RTi’s Executive Chairman and CEO, Dr. Brent Norton.  “We believe that Ortho-R holds great promise for improving the repair of soft tissue injuries, including rotator cuff tears, the meniscus in knees and articular cartilage.  As such, it is important to ensure that the potential market opportunity we see ahead is well protected.”

About Ortho Regenerative Technologies Inc.

Ortho RTi is an emerging Orthopaedic and Sports Medicine technology company dedicated to the development of novel therapeutic tissue repair devices to dramatically improve the success rate of sports medicine surgeries.  Our proprietary biopolymer has been specifically designed to increase the healing rates of sports related injuries to ligaments, tendons and cartilage.  The polymer can be directly placed into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention.